About Nuvalent
Nuvalent is a company based in Cambridge (United States) founded in 2017.. Nuvalent has raised $185 million across 2 funding rounds from investors including Fidelity Investments, Janus Henderson Investors and Driehaus. The company has 142 employees as of December 31, 2024. Nuvalent offers products and services including Zidesamtinib, Neladalkib, and NVL-330. Nuvalent operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Mereo BioPharma, among others.
- Headquarter Cambridge, United States
- Employees 142 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Nuvalent, Inc.
-
Annual Revenue
$00as on Dec 31, 2024
-
Net Profit
$-260.76 M-106.59as on Dec 31, 2024
-
EBITDA
$-280.37 M-87.55as on Dec 31, 2024
-
Total Equity Funding
$185 M (USD)
in 2 rounds
-
Latest Funding Round
$135 M (USD), Series B
May 11, 2021
-
Investors
Fidelity Investments
& 11 more
-
Employee Count
142
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Nuvalent
Nuvalent is a publicly listed company on the NASDAQ with ticker symbol NUVL in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Nuvalent
Nuvalent offers a comprehensive portfolio of products and services, including Zidesamtinib, Neladalkib, and NVL-330. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Targets advanced ROS1-positive NSCLC in clinical trials.
Inhibits ALK-positive NSCLC for patient treatment.
Focuses on HER2-altered NSCLC in phase 1 studies.
Unlock access to complete
Unlock access to complete
Leadership Team
29 people
Software Development Team
7 people
Scientific Team
5 people
Human Resources and Administration
5 people
Product Management Team
4 people
Finance and Accounting
4 people
Senior Team
3 people
Data Analysis and Operations Team
3 people
Unlock access to complete
Funding Insights of Nuvalent
Nuvalent has successfully raised a total of $185M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $135 million completed in May 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Series B — $135.0M
-
First Round
First Round
(27 Jan 2021)
- Investors Count 12
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May, 2021 | Amount | Series B - Nuvalent | Valuation | Bain Capital Life Sciences | |
| Jan, 2021 | Amount | Series A - Nuvalent | Valuation | Deerfield |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Nuvalent
Nuvalent has secured backing from 12 investors, including institutional and venture fund investors. Prominent investors backing the company include Fidelity Investments, Janus Henderson Investors and Driehaus. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Healthcare ecosystem is supported through investment and innovation by Deerfield.
|
Founded Year | Domain | Location | |
|
Private investment firm focused on multiple sectors
|
Founded Year | Domain | Location | |
|
Venture capital fund focused on biotechnology startups
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Nuvalent
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Nuvalent
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Nuvalent Comparisons
Competitors of Nuvalent
Nuvalent operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Mereo BioPharma, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| domain | founded_year | HQ Location |
Therapeutics for cancer and rare diseases are developed.
|
|
| domain | founded_year | HQ Location |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Nuvalent
Frequently Asked Questions about Nuvalent
When was Nuvalent founded?
Nuvalent was founded in 2017 and raised its 1st funding round 4 years after it was founded.
Where is Nuvalent located?
Nuvalent is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Who is the current CEO of Nuvalent?
James Porter is the current CEO of Nuvalent.
Is Nuvalent a funded company?
Nuvalent is a funded company, having raised a total of $185M across 2 funding rounds to date. The company's 1st funding round was a Series A of $50M, raised on Jan 27, 2021.
How many employees does Nuvalent have?
As of Dec 31, 2024, the latest employee count at Nuvalent is 142.
What does Nuvalent do?
Nuvalent was founded in 2017 and is based in Cambridge, United States. Oncology therapeutics are developed by the company, with emphasis on ROS1-selective inhibitors for non-small cell lung cancer and central nervous system metastasis. Drug candidates such as NUV-520 and NUV-655 are advanced to address lung cancer, breast cancer, and additional tumor types in clinical settings.
Who are the top competitors of Nuvalent?
Nuvalent's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
What products or services does Nuvalent offer?
Nuvalent offers Zidesamtinib, Neladalkib, and NVL-330.
Is Nuvalent publicly traded?
Yes, Nuvalent is publicly traded on NASDAQ under the ticker symbol NUVL.
Who are Nuvalent's investors?
Nuvalent has 12 investors. Key investors include Fidelity Investments, Janus Henderson Investors, Driehaus, Deerfield, and Wellington.
What is Nuvalent's ticker symbol?
The ticker symbol of Nuvalent is NUVL on NASDAQ.